Steroids decrease prevalence of positive tuberculin skin test in rheumatoid arthritis: Implications on anti-TNF therapies

Interdisciplinary Perspectives on Infectious Diseases

Volumn 2014, Issue , 2014, Pages

  Agarwal, Shweta ^a   Das, Siddharth Kumar ^a   Agarwal, Girdhar G ^b   Srivastava, Ragini ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b UNIVERSITY OF LUCKNOW   (India)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; STEROID;

ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; STEROID THERAPY; TREATMENT DURATION; TUBERCULIN TEST;

EID: 84897859329     PISSN: 1687708X     EISSN: 16877098     Source Type: Journal    
DOI: 10.1155/2014/430134     Document Type: Article

References (35)

1. Mollgaard H., Experimental basis for the treatment of tuberculosis with sanocrysin. Ugeskr Laeger 1924 86 article 1035
2. Slot G., Deville P. M., Hill N. G., Williams B., Fridjohn M. H., Treatment of arthritis and rheumatism with gold. The Lancet 1934 223 5759 73 76 2-s2.0-50249237576
3. Forestier J., Rheumatoid arthritis and its treatment by gold salts. The Lancet 1934 224 5795 646 648 2-s2.0-0001710171
4. Bahr G. M., Rook G. A. W., Al-Saffar M., van Embden J., Stanford J. L., Behbehani K., Antibody levels to mycobacteria in relation to HLA type: evidence for non-HLA-linked high levels of antibody to the 65 kD heat shock protein of M. bovis in rheumatoid arthritis. Clinical and Experimental Immunology 1988 74 2 211 215 2-s2.0-0023768467
5. Yamada T., Nakajima A., Inoue E., Tanaka E., Hara M., Tomatsu T., Kamatani N., Yamanaka H., Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Annals of the Rheumatic Diseases 2006 65 12 1661 1663 2-s2.0-33751274843 10.1136/ard.2005.047274 (Pubitemid 44799684)
6. Wolfe F., Michaud K., Anderson J., Urbansky K., Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis and Rheumatism 2004 50 2 372 379 2-s2.0-1042290327 10.1002/art.20009 (Pubitemid 38198820)
7. Askling J., Fored C. M., Brandt L., Baecklund E., Bertilsson L., Cöster L., Geborek P., Jacobsson L. T., Lindblad S., Lysholm J., Rantapää-Dahlqvist S., Saxne T., Romanus V., Klareskog L., Feltelius N., Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis and Rheumatism 2005 52 7 1986 1992 2-s2.0-22244454407 10.1002/art.21137 (Pubitemid 40994319)
8. Carmona L., Hernández-García C., Vadillo C., Pato E., Balsa A., González-Alvaro I., Belmonte M. A., Tena X., Sanmartí R., Increased risk of tuberculosis in patients with rheumatoid arthritis. Journal of Rheumatology 2003 30 7 1436 1439 (Pubitemid 36835436)
9. Cush J. J., Safety overview of new disease-modifying antirheumatic drugs. Rheumatic Disease Clinics of North America 2004 30 2 237 255 2-s2.0-2542485453 10.1016/j.rdc.2004.02.003 (Pubitemid 38692559)
10. Keane J., Gershon S., Wise R. P., Mirabile-Levens E., Kasznica J., Schwieterman W. D., Siegel J. N., Braun M. M., Tuberculosis associated with infliximab, a tumor necrosis factor α -neutralizing agent. The New England Journal of Medicine 2001 345 15 1098 1104 2-s2.0-0035846326 10.1056/NEJMoa011110
11. Gómez-Reino J. J., Carmona L., Rodríguez Valverde V., Mola E. M., Montero M. D., Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis and Rheumatism 2003 48 8 2122 2127 2-s2.0-0041653315 10.1002/art.11137 (Pubitemid 36959191)
12. Dixon W. G., Hyrich K. L., Watson K. D., Lunt M., Galloway J., Ustianowski A., Symmons D. P. M., Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Annals of the Rheumatic Diseases 2010 69 3 522 528 2-s2.0-77949477575 10.1136/ard.2009.118935
13. Central TB Division,. Government of India, New Delhi, India, TB Epidemiology, TB India 2013, Revised National TB Control Programme, Annual status report: 19
14. Seal S. C., Bhattacharji L. M., Banerji A. K., Mazumdar S. M., A tuberculosis survey of rural areas in close proximity to an industrial town. Indian Journal of Tuberculosis 1954 1 3, article 116
15. Narian R., Geser A., Jambunathan M. V., M. Tuberculosis prevalence survey in Tumkur district. Indian Journal of Tuberculosis 1963 10 article 85
16. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S., Medsger T. A. Jr., Mitchell D. M., Neustadt D. H., Pinals R. S., Schaller J. G., Sharp J. T., Wilder R. L., Hunder G. G., The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988 31 3 315 324 2-s2.0-0023945481 (Pubitemid 18091653)
17. World Health Organization-Media Centre, Tuberculosis. Fact sheet No. 104, 2013, http://www.who.int/mediacentre/factsheets/fs104/en/
18. Yildirim C., Küçük A. I., Ongüt G., Oǧünç D., Colak D., Mutlu G., Evaluation of tuberculin reactivity in different age groups with and without BCG vaccination Mikrobiyoloji Bülteni 2009 43 1 27 35
19. Gustafson P., Lisse I., Gomes V., Vieira C. S., Lienhardt C., Nauclér A., Jensen H., Aaby P., Risk factors for positive tuberculin skin test in Guinea-Bissau. Epidemiology 2007 18 3 340 347 2-s2.0-34247251473 10.1097/01.ede.0000259987.46912.2b (Pubitemid 46624943)
20. Welty C., Burstin S., Muspratt S., Tager I. B., Epidemiology of tuberculous infection in a chronic care population. The American Review of Respiratory Disease 1985 132 1 133 136 2-s2.0-0021849120 (Pubitemid 15026200)
21. Bowerman R. J., Tuberculin skin testing in BCG-vaccinated populations of adults and children at high risk for tuberculosis in Taiwan. International Journal of Tuberculosis and Lung Disease 2004 8 10 1228 1233 2-s2.0-5644269102 (Pubitemid 39371836)
22. National Tuberculosis Institute, Bangalore, Tuberculosis in a rural population of south India: a five year epidemiological study. Bulletin of the World Health Organization 1974 51 article 473
23. Bartalesi F., Vicidomini S., Goletti D., Fiorelli C., Fiori G., Melchiorre D., Tortoli E., Mantella A., Benucci M., Girardi E., Cerinic M. M., Bartoloni A., QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. European Respiratory Journal 2009 33 3 586 593 2-s2.0-61649085318 10.1183/09031936.00107608
24. NC TB Control Program Policy Manual (Rev. 02/13), 2:4
25. Schatz M., Patterson R., Kloner R., Falk J., The prevalence of tuberculosis and positive tuberculin skin tests in a steroid treated asthmatic population. Annals of Internal Medicine 1976 84 3 261 265 2-s2.0-0017237793
26. World Health Organization,. Tuberculosis IGRA TB Tests Policy Statement, 2011, http://www.who.int/tb/laboratory/policy-statements/en
27. Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M., Lipsky P., Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. The Lancet 1999 354 9194 1932 1939 2-s2.0-0033524159 10.1016/S0140-6736(99)05246-0
28. Gardam M. A., Keystone E. C., Menzies R., Manners S., Skamene E., Long R., Vinh D. C., Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. The Lancet Infectious Diseases 2003 3 3 148 155 2-s2.0-0037373957 10.1016/S1473-3099(03)00545-0 (Pubitemid 36278124)
29. Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Burmester G. R., Emery P., Keystone E. C., Schiff M. H., van Riel P. L. C. M., Weinblatt M. E., Weisman M. H., Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Annals of the Rheumatic Diseases 2006 65 supplement 3 iii2 iii15 2-s2.0-33750307231 10.1136/ard.2006.061937 (Pubitemid 44629094)
30. British Thoracic Society Standards of Care Committee, BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF- α treatment. Thorax 2005 60 10 800 805 2-s2.0-25444517037 10.1136/thx.2005.046797 (Pubitemid 41475202)
31. Fonseca J. E., Lucas H., Canhão H., Duarte R., Santos M. J., Villar M., Faustino A., Raymundo E., Guidelines for the diagnosis and treatment of latent tuberculosis infection and active tuberculosis in patients with inflammatory joint diseases proposed for treatment with tumour necrosis factor α antagonist drugs. Revista Portuguesa de Pneumologia 2006 12 5 603 613 (Pubitemid 44725469)
32. Mariette X., Salmon D., RATIO Group, French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Annals of the Rheumatic Diseases 2003 62 8 791 792 2-s2.0-0242416978 10.1136/ard.62.8.791 (Pubitemid 36886422)
33. Beglinger C., Dudler J., Mottet C., Nicod L., Seibold F., Villiger P. M., Zellweger J., Screening for tuberculosis infection before initiation of anti-TNF- α therapy. Swiss Medical Weekly 2007 137 43-44 621 622 2-s2.0-36148969327 (Pubitemid 350114753)
34. Bélard E., Semb S., Ruhwald M., Werlinrud A. M., Soborg B., Jensen F. K., Thomsen H., Brylov A., Hetland M. L., Nordgaard-Lassen I., Ravn P., Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflammatory Bowel Diseases 2011 17 11 2340 2349 2-s2.0-79953112230 10.1002/ibd.21605
35. Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Weisman M., Emery P., Feldmann M., Harriman G. R., Maini R. N., Infliximab and methotrexate in the treatment of rheumatoid arthritis. The New England Journal of Medicine 2000 343 22 1594 1602 10.1056/NEJM200011303432202 (Pubitemid 32162982)